Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,606 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | recruiting | Phase 2 | 70 | Innate PharmaINDUSTRY | 5 | Jun 17, 2026 | clinicaltrials |
| NCT07164170 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | recruiting | Phase 2 | 86 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors |
| recruiting |
| Phase 1 |
| 180 |
| Novartis PharmaceuticalsINDUSTRY |
| 6 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05632913 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer | recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 | 160 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07572773 | CHAMP Lung Cancer Screening Program(CHAMP) | recruiting | N/A | 300 | Jill KolesarOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07603856 | A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer(REVIVE) | recruiting | Phase 2 | 39 | University of ChicagoOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649629 | Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway(INNOVA-LUNG) | recruiting | — | 70 | Regina Elena Cancer InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05257551 | Tempus Small Cell Lung Cancer Observational Study (Sculptor) | recruiting | — | 200 | Tempus AIINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05589818 | Pembrolizumab for Advanced NSCLC and PS 2-3 | recruiting | Phase 2 | 45 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06213532 | CONNECTing to LungCare | recruiting | N/A | 152 | University of California, San FranciscoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06364917 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | recruiting | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06866717 | Hybrid Prehabilitation Before Thoracic Surgery(HYBREATH) | recruiting | N/A | 38 | ADIR AssociationOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07646288 | Acute Effects of Visual Feedback-Assisted Inspiratory Muscle Training After Lobectomy | recruiting | N/A | 40 | Hacettepe UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00991094 | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06957314 | A Study of Hospital-at-Home for People Receiving Tarlatamab | recruiting | N/A | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07091305 | A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04332367 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | recruiting | Phase 2 | 59 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05419076 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07638891 | A Study of HDM2020 in Patients With Advanced Sq-NSCLC | recruiting | Phase 1 | 150 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05254782 | Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection | recruiting | — | 360 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05762731 | Screening for Lung Cancer in Subjects With Family History of Lung Cancer | recruiting | — | 1,520 | The University of Hong KongOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07001670 | Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection Surgery | recruiting | N/A | 40 | Istanbul UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07267000 | EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER(ImmuEX) | recruiting | N/A | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07637448 | EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC | recruiting | Phase 2 | 32 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07637474 | Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients | recruiting | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07633626 | Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib | recruiting | — | 24 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00451022 | Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | recruiting | — | 750 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02906943 | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation(OCTANE) | recruiting | — | 10,000 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 17, 2026source: clinicaltrials